Chemical destruction of the prostate by Prostalyser-1 and Prostalyser-2 solutions: an experimental study in dogs


Cite item

Full Text

Abstract

The aim of the study was elaboration of a new minimally invasive but effective alternative method of BPH treatment. The experiments
were carried out on 46 male dogs divided into two equal groups. 10 ml of Prostalyser-1 solution (natrii chloridi 9.5 g, dimethylsulfoxidi 0.5 g, aquae destill. Ad 1000.0 g) was given in a single injection into the prostates of the first group of animals. The same volume of Prostalyser-2 solution (spiritus ethilicus 96% - 76.5 g, DMSO 0.5 g, aq.destill ad 100.0 g) - into the prostates of the other group, respectively. The temperature of the solutions was +80°C. Within the first 2 months, essential disorders were observed in the cellular Na-pump, membrane permeability system, there were lobular and diffusive necroses in prostatic alveolar epithelium and a decrease of the prostate weight by 68-66%. This condition of the prostate persisted for 4-6 months. Prostalyser-1 and Prostalyser-2 solutions can be recommended as very prospective substances for chemical destruction of the prostate in case of BPH.

References

  1. Kupeli S., Baltachi S., Sougur Т. et al. A prospective randomized study of transurethral resection of the prostate and transurethral vaporization of the prostate as a therapeutic alternative in the management of men BPH. Eur. Urol. 1998; 24: 15-18.
  2. Mebust W. K., Hotgrewe H. I., Dowd J. B. et al. Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J. Urol. (Baltimore) 1989; 141: 243-247.
  3. Roehborn С. G. Standard surgical interventions TU1P/TURP/ OPSU. In: Kirly R., McConnel J. D., Fitzpatrik J. M., Roehborn C. G. Boyl Peds: Textbook of benign prostatic hyperplasia. Oxford: Ysis Medical Media; 1996; vol. 2: 341-378.
  4. Roos N. P., Wenberg J. E., Malenka D. T. et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N. Engl. J. Med. 1989; 320: 1120-1124.
  5. Le May K. The first clinical investigation of transurethral hyperthermia by BPH in Canada. Eur. Urol. 1992; 21: 184-186.
  6. Okhara M., Akimoto M. Clinical results of hyperthermal treatment of BPH by using of "Thermex-П". Jpn. J. Endourol. ESWL 1992; 5 (1): 20-25.
  7. Ghoughuru A., Mautik A. K. Evaluation of the rolex of injection therapy for benign prostate hypertrophy. Br. J. Urol. 1980; 52 (3): 204-207.
  8. Angell J. С. Treatment of benign prostatic hyperplasia by phenol injection. Br. J. Urol. 1969; 41: 735-738.
  9. Managadze G., Tsintsadze O., Chigogidze Т., Managadze L. Mophological changes in prostate after ethanol injection. Clin. Expert Urol. (Tbilisi) 1995; 18: 44-46.
  10. Savoca G., De Stefani S., Gattuccio I. et al. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur. Urol. 2001; 40: 504-508.
  11. Plants M. K., Gross A. L., Kliment J. et al. lntraprostatic ethanol chemoablation via transurethral and transperineal injection. Br. J. Urol. Int. 2003; 91 (1): 94-99.
  12. Goya N., Ishikawa N., Ito F. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J. Urol. (Baltimore) 1999; 162: 383.
  13. Ditrolic J., Patel P., Watson R. A., Irwin I. J. Chemoablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J. Urol. (Baltimore) 2002; 167: 2100-2104.
  14. Shioshvili T. J. Method of BPH treament. Patent certificate #2173, 1998, Tbilisi, Georgia.
  15. Leninger A. The molecular basis of cell structure and function. New York: Worth Publishers Inc; 1972.
  16. Lwanga S. К., Туе С. Y. Manual of medical statistics. Geneva: WHO; 1989.
  17. Машковский М. Д. Лекарственные средства. М.: Медицина; 1984; т. 1: 202-203.
  18. Bouroncle В. A., Aschenbrand J. F., Todd H. Т. Comparative study of the effectiveness of DMSO and PVP in the preservation of human leukemic blood cells at -SOX. Cryobiology 1970; 6 (5): 409.
  19. Muschter R. Conductive heat: hot water-induced thermotherapy for ablation of prostatic tissue. J. Endourol. 2003; 17 (8): 609- 616.
  20. Walsh P. С. Benign prostatic hyperplasia. Campbell's Urol. 1979;2:949-961.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies